Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Xbrane Biopharma AB ( (SE:XBRANE) ) is now available.
Xbrane Biopharma AB has completed a directed share issue, resulting in a significant change in its registered share capital and total shares. This move is expected to impact the company’s financial structure and potentially strengthen its market position, reflecting its ongoing strategic initiatives to enhance growth and shareholder value.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology designed to reduce production costs. The company focuses on biosimilar candidates with an estimated market potential of EUR 23 billion in annual peak sales. Xbrane’s lead product, Ximluci®, has received market authorization in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 18,348,362
Technical Sentiment Signal: Sell
Current Market Cap: SEK417.4M
For detailed information about XBRANE stock, go to TipRanks’ Stock Analysis page.